(Q43046523)

English

A randomized trial to assess the efficacy of interferon-alpha daily in combination with ribavirin in the treatment of naïve patients with chronic hepatitis C.

scientific article published in September 2003

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

A randomized trial to assess the efficacy of interferon-alpha daily in combination with ribavirin in the treatment of naïve patients with chronic hepatitis C. (English)

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

1 reference

based on heuristic

inferred from title

author name string

N C Tassopoulos

1

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

I Ketikoglou

2

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

D Tsantoulas

3

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

M Raptopoulou

4

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

G Hatzis

5

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

I Vafiadis

6

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

L Sidiropoulos

7

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

S Kanatakis

8

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

G Anagnostopoulos

9

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

V Sypsa

10

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

A Hatzakis

11

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Hellenic Viral Hepatitis Research Network

12

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

publication date

1 September 2003

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Journal of Viral Hepatitis

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

10

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

5

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

383-389

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2003.00439.X

21 January 2018

Randomised, double-blind, placebo-controlled trial of interferon alpha-2b with and without ribavirin for chronic hepatitis C. The Swedish Study Group

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2003.00439.X

21 January 2018

Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (I

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2003.00439.X

21 January 2018

Evaluation of long-term efficacy of interferon alpha-2b and ribavirin in combination in naive patients with chronic hepatitis C: an Italian multicenter experience. Ribavirin-Interferon in Chronic Hepatitis Italian Group Investigators.

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2003.00439.X

21 January 2018

Interferon alfa with or without ribavirin for chronic hepatitis C: systematic review of randomised trials

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2003.00439.X

21 January 2018

Combination of interferon induction therapy and ribavirin in chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2003.00439.X

21 January 2018

Effect of combined interferon-alpha induction therapy and ribavirin on chronic hepatitis C virus infection: a randomized multicentre study

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2003.00439.X

21 January 2018

Cost effectiveness of combination therapy for hepatitis C: a decision analytic model

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2003.00439.X

21 January 2018

A randomized trial of amantadine and interferon versus interferon alone as initial treatment for chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2003.00439.X

21 January 2018

Interferon and amantadine in naive chronic hepatitis C: a double-blind, randomized, placebo-controlled trial.

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2003.00439.X

21 January 2018

A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2003.00439.X

21 January 2018

Peginterferon alfa-2a in patients with chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2003.00439.X

21 January 2018

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2003.00439.X

21 January 2018

A dose-ranging study of pegylated interferon alfa-2b and ribavirin in chronic hepatitis C. The Hepatitis C Intervention Therapy Group

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2003.00439.X

21 January 2018

Efficacy of 5 MU of interferon in combination with ribavirin for naïve patients with chronic hepatitis C virus: a randomized controlled trial.

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2003.00439.X

21 January 2018

Efficacy of a short-term ribavirin plus interferon alpha combination therapy followed by interferon alpha alone in previously untreated patients with chronic hepatitis C: a randomized multicenter trial

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2003.00439.X

21 January 2018

Combination of ribavirin and interferon-alfa surpasses high doses of interferon-alfa alone in patients with genotype-1b-related chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2003.00439.X

21 January 2018

High doses of interferon in combination with ribavirin are more effective than the standard regimen in patients with HCV genotype 1 chronic hepatitis.

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2003.00439.X

21 January 2018

Daily or three times a week interferon alfa-2b in combination with ribavirin or interferon alone for the treatment of patients with chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2003.00439.X

21 January 2018

High sustained response to daily dosing of interferon with ribavirin in chronic hepatitis C patients naïve to therapy

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2003.00439.X

21 January 2018

Early viral clearance and sustained response in chronic hepatitis C: a controlled trial of interferon and ribavirin after high-dose interferon induction.

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2003.00439.X

21 January 2018

Estimation of early hepatitis C viral clearance in patients receiving daily interferon and ribavirin therapy using a mathematical model

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2003.00439.X

21 January 2018

Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C: Effects of dose and duration

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2003.00439.X

21 January 2018

Interferon and amantadine in combination as initial treatment for chronic hepatitis C patients

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2003.00439.X

21 January 2018

Efficacy and safety of pegylated (40-kd) interferon alpha-2a compared with interferon alpha-2a in noncirrhotic patients with chronic hepatitis C

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2003.00439.X

21 January 2018

Identifiers

10.1046/J.1365-2893.2003.00439.X

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q43046523&oldid=1590552516"